A citation-based method for searching scientific literature

Teruo Shiba, So Ishii, Tomoo Okamura, Rika Mitsuyoshi, Egon Pfarr, Kazuki Koiwai. Diabetes Res Clin Pract 2017
Times Cited: 4







List of co-cited articles
4 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
75

Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study.
Takashi Kadowaki, Masakazu Haneda, Nobuya Inagaki, Yasuo Terauchi, Atsushi Taniguchi, Kazuki Koiwai, Henning Rattunde, Hans J Woerle, Uli C Broedl. Adv Ther 2015
34
50

Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.
Michael Roden, Ludwig Merker, Anita Vedel Christiansen, Flavien Roux, Afshin Salsali, Gabriel Kim, Peter Stella, Hans J Woerle, Uli C Broedl. Cardiovasc Diabetol 2015
68
50

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
50

Nondissection method in distal arterial bypass surgery.
O Sato, T Miyata, S Shindo, Y Takayama, Y Tada. Acta Chir Belg 1999
3
33

Preoperative Non-ambulatory Status Predicts Poor Outcome after Below Knee Bypass Surgery.
Kota Yamamoto, Tadashi Kitaoka, Harunobu Matsumoto, Juno Deguchi, Osamu Sato. Ann Vasc Dis 2011
5
25

Nondissection method for tibial bypass surgery using Esmarch's rubber bandage or an automatic sequential pneumatic tourniquet: long-term results.
S Shindo, K Iyori, M Kobayashi, O Suzuki, K Kamiya, Y Tada, Y Takayama, T Miyata, O Sato, A Takagi. Cardiovasc Surg 1998
9
25

Costs of COPD in Sweden according to disease severity.
Sven-Arne Jansson, Fredrik Andersson, Sixten Borg, Asa Ericsson, Elsy Jönsson, Bo Lundbäck. Chest 2002
122
25

The cost of moderate and severe COPD exacerbations to the Canadian healthcare system.
N Mittmann, L Kuramoto, S J Seung, J M Haddon, C Bradley-Kennedy, J M Fitzgerald. Respir Med 2008
124
25

The direct medical cost of diabetes in Israel.
Gabriel Chodick, Anthony D Heymann, Francis Wood, Ehud Kokia. Eur J Health Econ 2005
15
25

Resource use and risk factors in high-cost exacerbations of COPD.
Jan B Oostenbrink, Maureen P M H Rutten-van Mölken. Respir Med 2004
108
25

The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI).
Joseph L Mills, Michael S Conte, David G Armstrong, Frank B Pomposelli, Andres Schanzer, Anton N Sidawy, George Andros. J Vasc Surg 2014
600
25

Cost-effectiveness analysis of different systolic blood pressure targets for people with a history of stroke or transient ischaemic attack: Economic analysis of the PAST-BP study.
Maria Cristina Penaloza-Ramos, Sue Jowett, Pelham Barton, Andrea Roalfe, Kate Fletcher, Clare J Taylor, Fd Richard Hobbs, Richard J McManus, Jonathan Mant. Eur J Prev Cardiol 2016
8
25

The direct medical cost of cardiovascular diseases, hypertension, diabetes, cancer, pregnancy and female infertility in a large HMO in Israel.
Gabriel Chodick, Avi Porath, Hillel Alapi, Tal Sella, Shira Flash, Francis Wood, Varda Shalev. Health Policy 2010
29
25

Endovascular treatment of diabetic peripheral arterial disease in older and oldest old patients: a retrospective study.
Cristina Gatti, Sara Cecchini, Paolo Fabbietti, Fabio Romagnoli, Stefano Ricci. Aging Clin Exp Res 2018
2
50

Epidemiology of diabetes mellitus in old age in Japan.
Tadasumi Nakano, Hideki Ito. Diabetes Res Clin Pract 2007
19
25

[Diabetes and cardiovascular disease in NIPPON DATA].
Aya Kadota, Katsuyuki Miura, Hirotsugu Ueshima. Nihon Rinsho 2010
3
33

The Economic Costs of Type 2 Diabetes: A Global Systematic Review.
Till Seuring, Olga Archangelidi, Marc Suhrcke. Pharmacoeconomics 2015
338
25

Our treatment strategy for critical limb ischemia.
Tetsuo Yamada, Kiyoshi Onishi, Makoto Utsunomiya, Masato Nakamura. Int J Vasc Med 2013
5
25



Costs related to medical treatment for common cardiovascular risk factors.
P Turek, J Lietava, V Foltan, V Kosmalova, A Dukat. Bratisl Lek Listy 2010
2
50


A medical costs study of older patients with acute myocardial infarction and metabolic syndrome in hospital.
Guan-qi Fan, Kai-li Fu, Cheng-wei Jin, Xiao-zhen Wang, Lu Han, Hui Wang, Ming Zhong, Yun Zhang, Wei Zhang, Zhi-hao Wang. Clin Interv Aging 2015
7
25


Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial.
Atsushi Tanaka, Michio Shimabukuro, Yosuke Okada, Isao Taguchi, Minako Yamaoka-Tojo, Hirofumi Tomiyama, Hiroki Teragawa, Seigo Sugiyama, Hisako Yoshida, Yasunori Sato,[...]. Cardiovasc Diabetol 2017
24
25


Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
Eirik Søfteland, Juris J Meier, Bente Vangen, Robert Toorawa, Mario Maldonado-Lutomirsky, Uli C Broedl. Diabetes Care 2017
63
25


Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension.
Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra Green, Afshin Salsali, Uli C Broedl, Hans J Woerle. Diabetes Care 2015
281
25

Measuring inconsistency in meta-analyses.
Julian P T Higgins, Simon G Thompson, Jonathan J Deeks, Douglas G Altman. BMJ 2003
25


The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration.
Alessandro Liberati, Douglas G Altman, Jennifer Tetzlaff, Cynthia Mulrow, Peter C Gøtzsche, John P A Ioannidis, Mike Clarke, P J Devereaux, Jos Kleijnen, David Moher. BMJ 2009
25

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
298
25


Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®.
Kohei Kaku, Jisoo Lee, Michaela Mattheus, Stefan Kaspers, Jyothis George, Hans-Juergen Woerle. Circ J 2017
71
25

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
256
25

Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.
E Araki, Y Tanizawa, Y Tanaka, A Taniguchi, K Koiwai, G Kim, A Salsali, H J Woerle, U C Broedl. Diabetes Obes Metab 2015
39
25

Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
Mikhail Kosiborod, Matthew A Cavender, Alex Z Fu, John P Wilding, Kamlesh Khunti, Reinhard W Holl, Anna Norhammar, Kåre I Birkeland, Marit Eika Jørgensen, Marcus Thuresson,[...]. Circulation 2017
464
25

The renal effects of SGLT2 inhibitors and a mini-review of the literature.
Vasileios Andrianesis, Spyridoula Glykofridi, John Doupis. Ther Adv Endocrinol Metab 2016
25
25


Japanese study of tofogliflozin with type 2 diabetes mellitus patients in an observational study of the elderly (J-STEP/EL): A 12-week interim analysis.
Kazunori Utsunomiya, Naoki Shimmoto, Masayuki Senda, Yuji Kurihara, Ryoji Gunji, Hiroyuki Kameda, Masahiro Tamura, Hanako Mihara, Kohei Kaku. J Diabetes Investig 2016
9
25

Canagliflozin use in patients with renal impairment-Utility of quantitative clinical pharmacology analyses in dose optimization.
Manoj Khurana, Jayabharathi Vaidyanathan, Anshu Marathe, Nitin Mehrotra, Chandrahas G Sahajwalla, Issam Zineh, Lokesh Jain. J Clin Pharmacol 2015
4
25

Management of type 2 diabetes: new and future developments in treatment.
Abd A Tahrani, Clifford J Bailey, Stefano Del Prato, Anthony H Barnett. Lancet 2011
328
25






A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans.
Martin C Michel, Eric Mayoux, Volker Vallon. Naunyn Schmiedebergs Arch Pharmacol 2015
29
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.